Better Buy: Illumina vs. Exelixis
Comparing Illumina (NASDAQ: ILMN) with Exelixis (NASDAQ: EXEL) feels like a mismatch. The former is a dominant provider of genome sequencers serving as -- some might argue -- the foundation for the future of medicine. The latter is a scrappy biotech stock that has found ways to survive, despite setbacks, for more than 25 years.
Regardless of previous success, investing is about the future. And the prospects for these two companies may not be as drastically different as you might think if you only looked at the past. So who wins in a contest between the $47 billion gene sequencing leader and the $7 billion biotech trying to stretch every dollar out of a drug it developed a decade ago?
Image source: Getty Images
Source Fool.com
